Akari Therapeutics to Present Its Phase III Plans at the International Pemphigus & Pemphigoid Foundation (IPPF) Patient Educa...
September 29 2020 - 9:29AM
Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage
biopharmaceutical company focused on innovative therapeutics to
treat orphan autoimmune and inflammatory diseases where complement
(C5) and/or leukotriene (LTB4) systems are implicated, today
announced that Miles Nunn, Ph.D., Chief Scientific Officer of Akari
Therapeutics, and James Fettiplace, M.D., Medical Director, Akari
Therapeutics, will present the Company’s Phase III planned pivotal
study of nomacopan in patients with moderate to severe bullous
pemphigoid (BP) at the International Pemphigus & Pemphigoid
Foundation (IPPF) Virtual Patient Education Conference.
The IPPF’s main focus is to improve the quality of life for all
those affected by pemphigus and pemphigoid through early diagnosis
and support. The 2020 Virtual Patient Education Conference will be
an educational event for all stakeholders in the field of bullous
disease as the conference will present on disease research and
trends, educate on disease management, and elevate awareness.
“The IPPF community is excited to have Akari Therapeutics
participating in the 2020 IPPF Virtual Patient Education
Conference,” said Marc Yale, IPPF Advocacy & Research
Coordinator. “Research and drug development in pemphigoid are on
the horizon, and clinical trials, like the use of nomacopan in
bullous pemphigoid, will advance our understanding of the disease
and address the unmet medical need of patients. We are pleased to
be working together with patients, physicians, researchers, and
industry to ensure that we fulfil this promise."
“Akari very much looks forward to partnering with the IPPF to
understand as much as possible the perspective of patients and
carers in bullous pemphigoid. This vital understanding will ensure
that the Phase III study has patients at the center of our
thinking,” said James Fettiplace, Medical Director, Akari
Therapeutics.
Details of Akari’s presentation are as follows:
Event: |
|
2020 IPPF Virtual Patient Education Conference |
Session Title |
|
Current and Future Clinical Trials |
Session Date/Time: |
|
October 4, 2020, 3:30 pm - 5:30 pm PT (6:30 pm - 8:30 pm ET) |
Presentation Title: |
|
Pivotal-BP Study: Nomancopan for the Treatment of Moderate to
Severe BP |
To access the live webcast and subsequent archived recording of
the presentation, please visit the ‘Events’ page in the Investor
Relations section of the Company’s website at www.akaritx.com and
register for the IPPF conference. You may also register directly
for the IPPF conference here: IPPF Conference Registration.
About Akari Therapeutics
Akari is a biopharmaceutical company focused on developing
inhibitors of acute and chronic inflammation, specifically for the
treatment of rare and orphan diseases, in particular those where
the complement (C5) or leukotriene (LTB4) systems, or both
complement and leukotrienes together, play a primary role in
disease progression. Akari's lead drug candidate, nomacopan
(formerly known as Coversin), is a C5 complement inhibitor that
also independently and specifically inhibits leukotriene B4 (LTB4)
activity. Nomacopan is currently being clinically evaluated in four
target indications: bullous pemphigoid (BP), thrombotic
microangiopathy (TMA), atopic keratoconjunctivitis (AKC), and
COVID-19 pneumonia.
Cautionary Note Regarding Forward-Looking
Statements
Certain statements in this press release constitute
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995. You should not place
undue reliance upon the Company’s forward looking statements.
Except as required by law, the Company undertakes no obligation to
revise or update any forward-looking statements in order to reflect
any event or circumstance that may arise after the date of this
press release. These forward-looking statements reflect our current
views about our plans, intentions, expectations, strategies and
prospects, which are based on the information currently available
to us and on assumptions we have made. Although we believe that our
plans, intentions, expectations, strategies and prospects as
reflected in or suggested by those forward-looking statements are
reasonable, we can give no assurance that the plans, intentions,
expectations or strategies will be attained or achieved.
Furthermore, actual results may differ materially from those
described in the forward-looking statements and will be affected by
a variety of risks and factors that are beyond our control. Such
risks and uncertainties for our company include, but are not
limited to: needs for additional capital to fund our operations,
our ability to continue as a going concern; uncertainties of cash
flows and inability to meet working capital needs; an inability or
delay in obtaining required regulatory approvals for nomacopan and
any other product candidates, which may result in unexpected cost
expenditures; our ability to successfully develop nomacopan as a
treatment for COVID-19 related pneumonia and to successfully
commercialize any product in that indication; our ability to obtain
orphan drug designation in additional indications; risks inherent
in drug development in general and risks specific to the
development of potential treatments for COVID-19 related illnesses;
uncertainties in obtaining successful clinical results for
nomacopan and any other product candidates and unexpected costs
that may result therefrom; difficulties enrolling patients in our
clinical trials; our ability to enter into collaborative,
licensing, and other commercial relationships and on terms
commercially reasonable to us; failure to realize any value of
nomacopan and any other product candidates developed and being
developed in light of inherent risks and difficulties involved in
successfully bringing product candidates to market; inability to
develop new product candidates and support existing product
candidates; the approval by the FDA and EMA and any other similar
foreign regulatory authorities of other competing or superior
products brought to market; risks resulting from unforeseen side
effects; risk that the market for nomacopan may not be as large as
expected; risks associated with the impact of the outbreak of
coronavirus; risks associated with the SEC investigation; inability
to obtain, maintain and enforce patents and other intellectual
property rights or the unexpected costs associated with such
enforcement or litigation; inability to obtain and maintain
commercial manufacturing arrangements with third party
manufacturers or establish commercial scale manufacturing
capabilities; the inability to timely source adequate supply of our
active pharmaceutical ingredients from third party manufacturers on
whom the company depends; unexpected cost increases and pricing
pressures and risks and other risk factors detailed in our public
filings with the US Securities and Exchange Commission, including
our most recently filed Annual Report on Form 20-F filed with the
SEC. Except as otherwise noted, these forward-looking statements
speak only as of the date of this press release and we undertake no
obligation to update or revise any of these statements to reflect
events or circumstances occurring after this press release. We
caution investors not to place considerable reliance on the
forward-looking statements contained in this press release.
For more informationInvestor Contact:
Peter VozzoWestwicke(443) 213-0505peter.vozzo@westwicke.com
Media Contact:
Sukaina Virji / Lizzie SeeleyConsilium Strategic
Communications+44 (0)20 3709 5700Akari@consilium-comms.com
Akari Therapeutics (NASDAQ:AKTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Akari Therapeutics (NASDAQ:AKTX)
Historical Stock Chart
From Sep 2023 to Sep 2024